Valuation: Orion Oyj

Market Cap 11.69B 13.28B 11.08B 10B 18.85B 1,273B 19.1B 133B 51.01B 651B 49.86B 48.77B 2,087B P/E 2026 *
20.7x
P/E 2027 * 17.5x
Enterprise Value 11.6B 13.18B 10.99B 9.93B 18.71B 1,263B 18.95B 132B 50.62B 646B 49.48B 48.4B 2,071B EV / Sales 2026 *
5.53x
EV / Sales 2027 * 4.79x
Free-Float
90.5%
Yield 2026 *
2.34%
Yield 2027 * 2.61%
1 day+11.24%
Current month+11.24%
1 month+11.24%
3 months+11.24%
6 months+16.59%
Current year+13.22%
1 month 92.05
Extreme 92.05
92.05
Current year 78.95
Extreme 78.95
92.05
1 year 78.95
Extreme 78.95
92.05
3 years 47.16
Extreme 47.16
92.05
5 years 37
Extreme 37
92.05
10 years 27.35
Extreme 27.35
92.05
Manager TitleAgeSince
Chief Executive Officer 59 01/11/2022
Director of Finance/CFO 50 01/05/2024
Chief Operating Officer 46 01/01/2022
Director TitleAgeSince
Director/Board Member 63 22/03/2017
Director/Board Member 65 22/03/2017
Director/Board Member 66 06/05/2020
Change 5-day change 1-year change 3-year change Capi.($)
+11.24%0.00% - - 13.14B
-2.33%-1.12%+59.27%+115.42% 1,056B
-1.06%-1.65%+45.77%+69.98% 645B
-0.65%-1.36%+17.22%+75.49% 465B
-2.66%-3.71%+84.92%+41.15% 368B
-0.06%-4.12%+36.31%+39.39% 335B
-0.79%+3.01%+21.11%+27.79% 275B
-1.19%-3.09%+10.75%+10.61% 255B
-0.50%+2.75%+53.85%+56.84% 229B
-1.47%-2.37%+32.35%+98.89% 188B
Average +0.34%+0.12%+40.17%+59.51% 423.98B
Weighted average by Cap. -0.82%+0.30%+44.68%+71.39%

Financials

2026 *2027 *
Net sales 2.1B 2.38B 1.99B 1.79B 3.38B 228B 3.42B 23.77B 9.15B 117B 8.94B 8.75B 374B 2.37B 2.69B 2.25B 2.03B 3.83B 258B 3.88B 26.9B 10.35B 132B 10.12B 9.9B 423B
Net income 566M 642M 536M 484M 912M 61.58B 924M 6.41B 2.47B 31.48B 2.41B 2.36B 101B 668M 759M 633M 571M 1.08B 72.73B 1.09B 7.57B 2.91B 37.18B 2.85B 2.79B 119B
Net Debt -89.76M -102M -85.04M -76.78M -145M -9.77B -147M -1.02B -392M -5B -383M -374M -16.02B -333M -378M -315M -285M -537M -36.25B -544M -3.77B -1.45B -18.53B -1.42B -1.39B -59.42B
Logo Orion Oyj
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows: - innovative medicines (43%): for the treatment of cancer and pain management; - generic, OTC and biosimilar drugs (29.3%); - branded prescription products (16.6%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments; - veterinary products (7.5%); - pharmaceutical ingredients and outsourcing services (3.6%). Net sales break down primarily by source of revenue between sales of products (67.2%) and royalties (23.1%). Net sales are distributed geographically as follows: Finland (19.3%), Scandinavia (10%), Europe (28.1%), North America (25.5%) and other (17.1%).
Employees
4,000
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
83.10EUR
Average target price
76.67EUR
Spread / Average Target
-7.74%

Quarterly revenue - Rate of surprise